ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Merus NV

Merus NV (2GH)

41.40
-0.80
(-1.90%)
Closed 10 December 8:00AM
Realtime Data

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
41.40
Bid
40.80
Offer
42.00
Volume
978
39.60 Day's Range 42.80
21.40 52 Week Range 58.50
Previous Close
42.20
Open
42.80
Last Trade
40
@
41.2
Last Trade Time
Average Volume (3m)
127
Financial Volume
-
VWAP
-

2GH Latest News

Zwischenergebnisse der Monotherapie mit Petosemtamab von Merus zeigen weiterhin klinisch signifikante Aktivität bei 2L+ r/m HNSCC

Zwischenergebnisse der Monotherapie mit Petosemtamab von Merus zeigen weiterhin klinisch signifikante Aktivität bei 2L+ r/m HNSCC Studie mit Petosemtamab in Kombination mit Pembrolizumab bei 1L...

Les données intermédiaires de Merus portant sur le pétosemtamab continuent de démontrer une activité cliniquement significative dans le traitement de 2e ligne et lignes ultérieures du CETC r/m

Les données intermédiaires de Merus portant sur le pétosemtamab continuent de démontrer une activité cliniquement significative dans le traitement de 2e ligne et lignes ultérieures du CETC r/m...

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing...

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en fonction des données de sécurité et d’efficaci

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en...

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und Wirksamkeitsdaten aus der eNRGy-Studie bekannt

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und...

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy...

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts...

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive UTRECHT...

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02...

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024 – Petosemtamab 1500 mg monotherapy phase 2 interim data continues to...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-4.6-10464739.624844.22983871DE
4-10.1-19.611650485451.551.539.612544.72627361DE
12-3.8-8.4070796460245.251.539.612747.17167127DE
26-7.6-15.51020408164957.539.615948.54794972DE
5219.488.18181818182258.521.39999917544.36210739DE
15617.673.949579831923.858.51916742.00023485DE
26017.673.949579831923.858.51916742.00023485DE

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
NL8Genesis Ai Corp
0.035 €
(130.26%)
78.41k
C0MCCS Abwicklungs AG
0.30 €
(114.29%)
125.51k
2WOWide Open Agriculture Ltd
0.013 €
(85.71%)
35.39k
1UR1Bee Vectoring Technologies International Inc
0.0075 €
(50.00%)
261.4k
KEHChinese People Holdings Co Ltd
0.0045 €
(50.00%)
22.92k
Y7GBioAge Labs Inc
4.46 €
(-76.53%)
20.69k
4APApollo Minerals Ltd
0.005 €
(-41.18%)
49.2k
HF2Reflex Advanced Materials Corp
0.0136 €
(-38.18%)
11.9k
R1EAEV Resources Ltd
0.001 €
(-37.50%)
230.95k
NJF1Grid Metals Corp
0.016 €
(-37.25%)
2k
AXIAtos SE
0.0027 €
(-3.57%)
926.53M
D7GNel ASA
0.2699 €
(2.82%)
5.14M
3CPXiaomi Corporation
3.91 €
(8.34%)
4.02M
9SBSOL Global Investments Corp
0.28 €
(16.67%)
4M
POQ88 Energy Limited
0.001 €
(-16.67%)
2.87M

Discussion

View Full Feed
i_like_bb_stock i_like_bb_stock 4 minutes ago
Yea and gvsi has nothing going for it 
BCDS
GrandAdmiralThrawn GrandAdmiralThrawn 4 minutes ago
Got that message CJ2 appreciate the heads up
HMBL
AlwaysKing AlwaysKing 5 minutes ago
$RDAR ~Actually I think it was the same investor(s) from the end of the day on Friday when we saw similar large buys coming in just before the close! All I know is that we are currently sitting at a market cap of just above a measly $11.4 million which means we have a huge upside potential which t
RDAR
surfer44 surfer44 5 minutes ago
Intermission

https://youtu.be/Ou87zFVf59E
Toronto_Trader Toronto_Trader 6 minutes ago
Very nice volume starting to come in. Did anyone notice we did more volume than GVSI which has been on the up and up following HMBL lately?

I think we do a 100 mil + day soon and crack $0.01 easily.

$BCDS
BCDS GVSI HMBL
DonVance DonVance 6 minutes ago
Want to make a friendly wager? If it never hits .08 again I will venmo you $100. If it does, you find something more productive to do with your valuable time than posting on this board ever again.
CBDS
gfp927z gfp927z 6 minutes ago
Xena, The link you posted on the AVXL board isn't working, but is the type of product you are taking --> MCT (medium-chain triglycerides)? If so, Dr. Gundry has this MCT product -

https://www.amazon.com/Gundry-MD-Wellness-Production-Raspberry/dp/B0C78JW6V2

https://gu
AVXL
peanutz peanutz 7 minutes ago
You take the 16?
SOUN
Toronto_Trader Toronto_Trader 8 minutes ago
Looking way too good right now! My only regret is not buying more last week. May have throw some more at this beast tomorrow.

$BCDS
BCDS
Konaploinks Konaploinks 8 minutes ago
Give it up basher boy. No one wants to hear your drivel so go home to Jensen and tell him you’ve been shut down. Nvda is toast. Dead money. That’s why I sold 3 months ago and bought Ionq ,but like d a you held while my investment gained 300 % Bwaaaeaaaaahahaha
IONQ
arizona1 arizona1 9 minutes ago
Is Olives a home insurance fanboy as well?
3331 3331 9 minutes ago
BIEL: BUY RATING
https://www.barchart.com/stocks/quotes/BIEL/opinion
Ribo Ribo 10 minutes ago
Audited financials and merger details coming!!!
https://x.com/CoachBarry18/status/1866251227568181304
EEGI
3331 3331 10 minutes ago
BIEL: BUY RATING
https://www.barchart.com/stocks/quotes/BIEL/opinion
janice shell janice shell 10 minutes ago
I think you may be right about happiness...
Doc logic Doc logic 10 minutes ago
exwannabe,

No, even if PFS had been positive the cost and limitations of artisan production getting past product release issues would have kept them from submitting for approval. Long term OS benefit would not have been established by them ending the trial early and would have left t
NWBO
surfer44 surfer44 11 minutes ago
The War on Gold and Individual Freedom Intensifies.

https://youtu.be/xXmf9k-XSl0
HoldEm777 HoldEm777 12 minutes ago
Just looking from a shorter term perspective I suppose. I guess someone has to buy top and sell bottom in the short term waves. I might as well not alert the sheep so I can grade higher. Maybe even get graded at “C” trader status…. Lol.
I guess if I had a real concern short term it would be
RDAR
TheSprinx TheSprinx 12 minutes ago

Well at least the new CEO liked my reply to his X post.

HMBL
G_rokk G_rokk 14 minutes ago
FDA approves drugs that can cause sudden death or cancer . Those are extreme side effects but yet those drugs got approval . Vivos should be granted IDE yesterday . We all know human trials of RADIOGEL wont kill the patient or cause a cancer . Its been proven in many animals . But here we are in a
RDGL
weedtrader420 weedtrader420 14 minutes ago
Somebody call the cops were being robbed🙁🔫🫲🎅🪙🪙🪙🪙🪙
XRPUSD
georgejjl georgejjl 15 minutes ago
The Model Q is not the Cybercab

Tesla Confirms Sub-$30,000 'Model Q' For 2025

https://insideevs.com/news/743793/tesla-model-q-2025-30000/

Good luck and GOD bless,
TSLA
dinogreeves dinogreeves 16 minutes ago
47 prints and 46 prints overnight.
SMCI
Chartmaster Chartmaster 17 minutes ago
Yup, excellent chart and volume!!! News too! and momentum!
GRLT

Your Recent History

Delayed Upgrade Clock